Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not
express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth …

Triple negative breast cancer (TNBC) is an aggressive breast cancer with historically poor
outcomes, primarily due to the lack of effective targeted therapies. The tumor molecular …

Breast cancer has historically been a disease for which immunotherapy was largely
unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with …

Advances in computational algorithms and tools have made the prediction of cancer patient
outcomes using computational pathology feasible. However, predicting clinical outcomes …

Triple-negative breast cancer (TNBC) is a heterogeneous disease with poorer outcomes
compared to other breast cancer subtypes. Contributing to the worse prognosis in TNBC is …

Purpose To evaluate the association between PD-L1 expression (PD-L1+) and
clinicopathological characteristics and effect on prognosis in primary breast cancer (PBC) …

Breast cancer represents a heterogeneous group of human cancer at both histological and
molecular levels. Estrogen receptor (ER), progesterone receptor (PR) and human epidermal …

Although immune checkpoint blockade have demonstrated promising results, their effects on
gastric cancer (GC) are under investigation. Understanding the clinical significance of PD1 …

Simple Summary The tumor microenvironment (TME) is a complicated network composed of
various cells, signaling molecules, and extra cellular matrix. TME plays a crucial role in triple …

Immunohistochemistry is an essential component of diagnostic breast pathology. The
emergence of novel assays and applications is accompanied by new interpretation criteria …